Avidity Partners Management’s Karyopharm Therapeutics KPTI Stock Holding History

Avidity Partners Management’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9.03M	Buy	924,487 +460,746	+99%	+$4M	1.45%	13
2026 Q1	$2.58M	Buy	463,741 +329,175	+245%	+$2.51M	0.52%	21
2025 Q4	$990K	Hold	134,566	–	–	0.29%	38
2025 Q3	$880K	Hold	134,566	–	–	0.2%	42
2025 Q2	$580K	Hold	134,566	–	–	0.12%	53
2025 Q1	$503K	Sell	134,566 -1	-0%	-$9	0.1%	64
2024 Q4	$1.37M	Hold	134,567	–	–	0.13%	61
2024 Q3	$1.68M	Hold	134,567	–	–	0.09%	78
2024 Q2	$1.75M	Sell	134,567 -418,671	-76%	-$6.93M	0.07%	81
2024 Q1	$12.5M	Hold	553,238	–	–	0.4%	65
2023 Q4	$7.18M	Hold	553,238	–	–	0.26%	64
2023 Q3	$11.1M	Sell	553,238 -4,769	-0.9%	-$107K	0.45%	64
2023 Q2	$15M	Sell	558,007 -84,254	-13%	-$3.63M	0.52%	64
2023 Q1	$37.5M	Hold	642,261	–	–	1.24%	32
2022 Q4	$32.8M	Buy	+642,261	New	+$44.5M	0.71%	41

Other funds holding KPTI

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

CCM

Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

KCM

Kalehua Capital Management Dallas, Texas $174M AUM

Avidity Partners Management's KPTI Position: Q2 2026 in Review

Avidity Partners Management increased its Karyopharm Therapeutics (KPTI) stake by 99% in Q2 2026, buying an estimated $4M and bringing the position to 924,487 shares worth $9.03M. The position accounts for 1.45% of the portfolio, ranked #13.

Avidity Partners Management first reported a position in KPTI in Q4 2022 and has held it in 15 quarters since. The position peaked at $37.5M in Q1 2023. 97 funds tracked by Wall St. Rank hold KPTI as of Q2 2026.

Avidity Partners Management held 924,487 shares of Karyopharm Therapeutics worth $9.03M as of Q2 2026.
Avidity Partners Management bought 460,746 Karyopharm Therapeutics shares in Q2 2026, an estimated $4M.
Karyopharm Therapeutics made up 1.45% of Avidity Partners Management's portfolio in Q2 2026, its #13 holding.
Avidity Partners Management first reported a position in Karyopharm Therapeutics in Q4 2022 and has held it in 15 quarters since.
Avidity Partners Management's Karyopharm Therapeutics position peaked at $37.5M in Q1 2023.
97 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2026.

Based on Avidity Partners Management's 13F filing for Q2 2026, filed 14 Aug 2026.